Cardiovascular Diabetology

Table 2 Renal and intraglomerular hemodynamics

From: Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

	E+L group				M + I group				E+L vs. M+I
Parameter	Baseline	12 weeks	Δ	p-value	Baseline	12 weeks	Δ	p-value	p_adjust-value
RPF (ml/min)^*	623 ± 114	615 ± 115	− 7.6 ± 86	0.536	653 ± 150	600 ± 121	− 52 ± 94	< 0.001	0.041
GFR (ml/min)^†	127 ± 13	120 ± 14	− 6.3 ± 12	0.003	127 ± 15	120 ± 13	− 6.7 ± 10	0.001	0.899
FF (%)^†	21.6 ± 3.1	20.9 ± 3.0	− 0.7 ± 2.7	0.151	21.2 ± 2.8	21.5 ± 3.2	0.38 ± 2.2	0.337	0.200
RBF (ml/min)^*	1061 ± 199	1113 ± 220	53 ± 157	0.021	1112 ± 249	1036 ± 217	− 76 ± 159	0.002	< 0.001
RVR (mmHg)^*	91 ± 20	84 ± 18	− 7 ± 15	0.001	87 ± 21	94 ± 21	7 ± 13	0.001	< 0.001
P_glom (mmHg)^†	61.6 ± 3.2	61.1 ± 3.4	− 0.46 ± 3.1	0.387	61.7 ± 3.1	60.9 ± 3.2	− 0.86 ± 2.6	0.073	0.661
R_A (dyn*s/cm⁵)^†	2547 ± 880	2358 ± 734	− 189 ± 685	0.116	2579 ± 798	2835 ± 800	256 ± 485	0.006	0.023
R_E (dyn*s/cm⁵)^†	2361 ± 407	2152 ± 389	− 208 ± 330	0.001	2316 ± 351	2349 ± 435	33 ± 298	0.538	0.011
R_E/R_A (−)^†	1.02 ± 0.36	1.01 ± 0.37	− 0.01 ± 0.4	0.836	0.96 ± 0.25	0.87 ± 0.2	− 0.09 ± 0.17	0.004	0.597
MAP (mmHg)	93.4 ± 8.6	90.3 ± 8.0	− 3.1 ± 8.0	0.009	92.5 ± 7.2	93.4 ± 6.8	1.0 ± 5.9	0.264	0.021

Dara are means ± SD
^* N = 50 (E+L group) and N = 46 (M+I group), respectively
^†N = 34 (E+L group) and N = 31 (M+I group), respectively

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com